ProfileGDS5678 / 1417173_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 74% 72% 79% 73% 73% 73% 73% 73% 75% 74% 73% 73% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5646572
GSM967853U87-EV human glioblastoma xenograft - Control 24.7922574
GSM967854U87-EV human glioblastoma xenograft - Control 34.5787472
GSM967855U87-EV human glioblastoma xenograft - Control 45.6224979
GSM967856U87-EV human glioblastoma xenograft - Control 54.7097873
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6660473
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6748773
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7227373
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6649573
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9315875
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7869574
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7268573
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7345273
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7358473